• 2019-10
  • 2019-11
  • 2020-03
  • 2020-07
  • 2020-08
  • 2021-03
  • br Danen Van Oorschot AA Fischer


    [22] Danen-Van Oorschot AA, Fischer DF, Grimbergen JM, Klein B, Zhuang S, Falkenburg JH, et al. Apoptin induces apoptosis in human transformed and malignant BCI-121 but not in normal cells. Proc Natl Acad Sci U S A 1997;94:5843–57.
    [23] Guelen L, Paterson H, Gaken J, Meyers M, Farzaneh F, Tavassoli M. TAT-apoptin is efficiently delivered and induces apoptosis in cancer cells. Oncogene 2004;23:1153–65.
    [24] Pietersen AM, van der Eb MM, Rademaker HJ, van den Wollenberg DJ, Rabelink MJ, Kuppen PJ, et al. Specific tumor-cell killing with adenovirus vectors containing the apoptin gene. Gene Ther 1999;6: 882–92.
    [25] Zhuang SM, Landegent JE, Verschueren CA, Falkenburg JH, van Ormondt H, van der Eb AJ, et al. Apoptin, a protein encoded by chicken anemia virus, induces cell death in various human hemato-logic malignant cells in vitro. Leukemia 1995;9(Suppl 1):S118–20.
    [27] Lewis KA, Tollefsbol TO. Regulation of the telomerase reverse tran-scriptase subunit through epigenetic mechanisms. Front Genet 2016;7:83. 
    [29] Sitaram RT, Degerman S, Ljungberg B, Andersson E, Oji Y, Sugiyama H, et al. Wilms’ tumour 1 can suppress hTERT gene expression and telomerase activity in clear cell renal cell carcinoma via multiple pathways. Br J Cancer 2010;103:1255–62.
    [33] Qi Y, Guo H, Hu N, He D, Zhang S, Chu Y, et al. Preclinical pharma-cology and toxicology study of Ad-hTERT-E1a-Apoptin, a novel dual cancer-specific oncolytic adenovirus. Toxicol Appl Pharmacol 2014;280:362–9.
    [39] Hu JC, Coffin RS, Davis CJ, Graham NJ, Groves N, Guest PJ, et al. A phase I study of OncoVEXGM-CSF, a second-generation oncolytic herpes simplex virus expressing granulocyte macrophage colony-stimulating factor. Clin Cancer Res 2006;12:6737–47.
    [41] Fujii H, Noda K, Asami Y, Kuroda A, Sakata M, Tokida A. Increase in bioluminescence intensity of firefly luciferase using genetic modifi-cation. Anal Biochem 2007;366:131–6.
    [42] Marques SM, Esteves da Silva JC. Firefly bioluminescence: a mecha-nistic approach of luciferase catalyzed reactions. IUBMB Life 2009; 61:6–17.
    [46] Maddika S, Mendoza FJ, Hauff K, Zamzow CR, Paranjothy T, Los M. Cancer-selective therapy of the future: apoptin and its mechanism of action. Cancer Biol Ther 2006;5:10–9.
    [48] Bullenkamp J, Gaken J, Festy F, Chong EZ, Ng T, Tavassoli M. Apoptin interacts with and regulates the activity of protein kinase C beta in cancer cells. Apoptosis 2015;20:831–42.
    [52] Danen-Van Oorschot AA, Zhang YH, Leliveld SR, Rohn JL, Seelen MC, Bolk MW, et al. Importance of nuclear localization of apoptin for tumor-specific induction of apoptosis. J Biol Chem 2003;278:27729–36. 
    [53] Kuusisto HV, Wagstaff KM, Alvisi G, Jans DA. The C-terminus of apoptin represents a unique tumor cell-enhanced nuclear targeting module. Int J Cancer 2008;123:2965–9.
    [54] Wadia JS, Wagner MV, Ezhevsky SA, Dowdy SF. Apoptin/VP3 con-tains a concentration-dependent nuclear localization signal (NLS), not a tumorigenic selective NLS. J Virol 2004;78:6077–8.
    Contents lists available at ScienceDirect
    Taiwanese Journal of Obstetrics & Gynecology
    Original Article
    Antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET r> a Department of Medical Research, Mackay Memorial Hospital, New Taipei City, Taiwan
    b Department of Obstetrics and Gynecology, Mackay Memorial Hospital, Taipei, Taiwan
    c Department of Medicine, Mackay Medical College, Sanchi, New Taipei City, Taiwan
    Article history:
    Ovarian cancer
    Tyrosine kinase
    Objective: Tyrosine-protein kinase MET (c-MET) has been reported to be a prognostic marker and suit-able therapeutic target for ovarian cancer. BMS-777607, a small molecule, can inhibit MET and other protein kinase activities. The present study was conducted to investigate the mechanism of action and antitumor effect of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.
    Materials and methods: Ovarian cancer cells with constitutively activated c-MET were first identified through Western blot analysis. Bio-behaviors, including signal transduction, proliferation, apoptosis, and migration, of the cells with constitutively activated c-MET were evaluated after BMS-777607 treatment. Liu's stain and immunological staining of a-tubuline were performed to evaluate the ploidy of the cells. A xenograft mouse model was also used to evaluate the antitumor effects of BMS-777607 on ovarian cancer cells with constitutively activated c-MET.
    Results: BMS-777607 could induce the highest inhibition of cell growth in ovarian cancer cells consti-tutively expressing c-MET. Treating SKOV3 cells with BMS-777607 could reduce c-MET activation and inhibit downstream cell signaling, thus causing cell apoptosis and polyploidy as well as cell cycle and cell migration inhibition. This molecule also inhibited tumor growth in a mouse xenograft model of SKOV3 ovarian cancer cells in vivo.